• linkedin
  • Increase Font
  • Sharebar

    FDA approves first combo therapy for advanced melanoma

    FDA has approved trametinib (Mekinist, GlaxoSmithKline) in combination with dabrafenib (Tafinlar, GlaxoSmithKline) to treat patients with advanced melanoma that is unresectable or metastatic.

    FDA approved both drugs in May 2013 as single agents to treat patients with unresectable or metastatic melanoma. Melanoma is the most aggressive type of skin cancer and is the leading cause of death from skin disease. According to the Melanoma Research Foundation (http://www.melanoma.org), one in 50 Americans has a lifetime risk of developing melanoma. In the United States in 2009, nearly 63,000 people were diagnosed with melanoma, resulting in approximately 8,650 deaths.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available